BPC-157 Oral (Gut) vs Butyrate
A side-by-side research comparison of BPC-157 Oral (Gut) and Butyrate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 Oral (Gut) | Butyrate |
|---|---|---|
| Full name | BPC-157 Oral (Stable Arginine Salt) | Sodium Butyrate / Tributyrin |
| Category | Gut Health | Gut Health |
| Status | Research compound | Dietary supplement |
| Mechanism | Upregulates VEGF and EGF receptors in GI mucosa, promotes angiogenesis at ulcer/lesion sites, modulates nitric oxide system, and interacts with dopamine and serotonin systems in the gut-brain axis. | Inhibits histone deacetylases (HDACs) for anti-inflammatory gene expression. Fuels colonocyte mitochondria via beta-oxidation. Strengthens tight junctions by upregulating claudin-1 and ZO-1. Activates GPR109A to suppress NF-κB. |
| Molecular weight | 1419 Da | 110.09 Da (sodium butyrate) |
| Half-life | ~4 hours (local GI transit) | ~30-40 minutes (rapidly metabolized by colonocytes) |
| Bioavailability | Limited systemic absorption; primary action is local GI | Tributyrin: ~60-80% delivery to colon; sodium butyrate: variable |
| Typical dose | 250-500 mcg | 300-600 mg tributyrin or 500-2000 mg sodium butyrate |
| Frequency | 2x daily on empty stomach | 2-3x daily with meals |
| Route | Oral capsule or sublingual | Oral (enteric-coated or tributyrin pro-drug) |
BPC-157 Oral (Gut) reported benefits
- Gastric ulcer healing
- Esophageal repair (GERD)
- Intestinal inflammation reduction
- IBD symptom relief
- Gut-brain axis support
- NSAID damage protection
Butyrate reported benefits
- Colonocyte energy support
- Tight junction integrity
- Reduced GI inflammation
- Healthy microbiome support
- Epigenetic modulation (HDAC inhibition)
- Improved insulin sensitivity
Related comparisons
Research and educational reference only. Not medical advice.